RPRX · Royalty Pharma plc
$64.76
+1.41% last session
End-of-day data · close of 2026-10-26
Market cap
$37B
Enterprise value
$40B
Trailing P/E
34.0
Forward P/E
11.0
Dividend yield
1.0%
Beta
0.41
Avg volume
3M
Employees
0K
Daily Change %
1.41%
5 Days Change
4.58%
10 Days Change
12.69%
30 Days Change
10.58%
60 Days Change
3.95%
Month to Day Change
10.62%
Year to Day Change
67.25%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RPRX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-07
Latest call per bank · past 12 months
Morgan Stanley
Overweight$67.00
+4.9% vs priceJP Morgan
Overweight$62.00
-2.9% vs priceCitigroup
Buy$66.00
+3.4% vs priceUBS
Buy$57.00
-10.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Morgan Stanley | Maintains | Overweight | $65.00 → $67.00 |
| 2026-09-08 | TD Cowen | Maintains | Buy | $65.00 → $68.00 |
| 2026-08-07 | JP Morgan | Maintains | Overweight | $58.00 → $62.00 |
| 2026-07-13 | TD Cowen | Maintains | Buy | $50.00 → $65.00 |
| 2026-05-07 | Citigroup | Maintains | Buy | $50.00 → $66.00 |
| 2026-05-07 | JP Morgan | Maintains | Overweight | $50.00 → $58.00 |
| 2026-04-21 | UBS | Maintains | Buy | $51.00 → $57.00 |
| 2026-04-10 | Morgan Stanley | Maintains | Overweight | $61.00 → $63.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- bearish: RSI (14): RSI is 73 — overbought territory; the recent run-up may be due for a pause.
- bullish: Price vs 50-day MA: Trading 8.2% above the 50-day MA ($59.84).
- bullish: Price vs 200-day MA: Trading 23.5% above the 200-day MA ($52.44).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.80) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($64.76).
RPRX Price Chart
Loading chart for RPRX…
Fundamentals
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
GMAB
Genmab A/S
$27B 29.9% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.